All In Biotech

Investigational drug · Phase 3

Zimislecel

Also called: Formerly known as STx-02, VX-880

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 1 Diabetes, Kidney Transplant, Diabetes Mellitus, Type 1.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Zimislecel"

First trial start

2021

Mar 29, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zimislecel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 1 Diabetes
  • Kidney Transplant
  • Diabetes Mellitus, Type 1
  • Impaired Hypoglycemic Awareness
  • Severe Hypoglycemia

Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Zimislecel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Type 1 Diabetes

  • THDB0206Phase 32 trials

    Tonghua Dongbao Pharmaceutical Co.,Ltd · Type 2 Diabetes, Type 1 Diabetes

  • CNP-103Phase 21 trial

    COUR Pharmaceutical Development Company, Inc. · Type 1 Diabetes Mellitus, T1D, T1DM

  • SAB-142Phase 21 trial

    SAb Biotherapeutics, Inc. · Type 1 Diabetes

  • VX-264Phase 21 trial

    Vertex Pharmaceuticals · Type 1 Diabetes

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.